mendeley

    Disease biology alters the response to frontline bortezomib, lenalidomide and dexamethasone in Multiple Myeloma

    DOI Logo 10.17352/2581-5407.000037

    Published On: February 13, 2021 | Pages: 010 - 015

    Author(s): Amany R Keruakous*, Silas Day and Carrie Yuen
    Background: Achievement of the best initial response to induction regimen in multiple myeloma is a prognostic factor for disease outcome. The triplet regimen-bortezomib, lenalidomide, and dexamethasone, VRd, is the preferred induction regimen in newly diagnosed Multiple Myeloma (MM) due to its favorable impact on overall survival. However, recent studies showed a deep ... CrossMark Publons Harvard Library HOLLIS Search IT Semantic Scholar Get Citation Base Search Scilit OAI-PMH ResearchGate Academic Microsoft GrowKudos
    Abstract View Full Article View
    mendeley

    Application of nano based drug delivery channel against leukemia chemotherapeutic resistance

    DOI Logo 10.17352/2581-5407.000036

    Published On: February 09, 2021 | Pages: 001 - 009

    Author(s): Rahul Bhattacharjee*, Olabimtan Olabode H, Ochigbo Victor and Samuel Florence
    To the management of leukemia, traditional chemotherapy is characterized by repeated dosage, adverse side effects, disruption to the immune system and other organs with rapidly proliferating cells due to non-specific targeting, insolubility, and failure to attack the tumor center, low survival treatment impairments, and resistance from the targeted cancerous cells. Th ... CrossMark Publons Harvard Library HOLLIS Search IT Semantic Scholar Get Citation Base Search Scilit OAI-PMH ResearchGate Academic Microsoft GrowKudos
    Abstract View Full Article View

     

    Global Views

    Case Reports

    Peertechz Tweets

    Pinterest on GJCT